Oncogenic β-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer

Andrei V. Ougolkov, Kaname Yamashita, Masayoshi Mai, Toshinari Minamoto*

*Corresponding author for this work

Research output: Contribution to journalArticle

116 Scopus citations


Background & Aims: Recent in vitro studies showed that β-catenin translocated into the tumor cell nucleus functions as an oncogene by transactivating oncogenes, including MMP-7. We conducted a large-scale analysis of β-catenin and MMP-7 expression in human colon cancer to determine the potential clinical importance of these molecules. Methods: In 202 colon cancer patients with known postoperative outcomes, we determined the expression of β-catenin and MMP-7 in the tumors immunohistochemically and correlated the findings with the patients' clinicopathological characteristics and survival. Results: We found 2 distinct patterns of β-catenin nuclear accumulation (NA) in the colon cancers: diffuse NA (NAd) in 89 cases (44%) and selective NA at the invasion front (NAinv) in 18 cases (9%). The presence of the NAinv pattern was significantly correlated with advanced Dukes' stage (P = 0.0187) and tumor recurrence (P = 0.0005) as well as with MMP-7 expression in the tumor invasion front (P = 0.0025), resulting in extremely unfavorable clinical outcomes. A multivariate analysis determined that the NAinv expression pattern and Dukes' C stage were independent prognostic factors. Conclusions: Oncogenic activation of β-catenin in the tumor invasion front, as represented by its NAinv pattern of expression, may be an independent and reliable indicator of membership in a subset of colon cancer patients who are highly susceptible to tumor recurrence and have a less favorable survival rate.

Original languageEnglish (US)
Pages (from-to)60-71
Number of pages12
Issue number1
StatePublished - 2002

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Oncogenic β-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer'. Together they form a unique fingerprint.

  • Cite this